Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
NCT00259753
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
Bevasiranib
Sponsor
OPKO Health, Inc.